Research ExplorerPublicationsDeterminants of survival in myelofibrosis patients undergoin...

Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Standard

Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. / Hernández-Boluda, Juan Carlos; Pereira, Arturo; Kröger, Nicolaus; Beelen, Dietrich; Robin, Marie; Bornhäuser, Martin; Angelucci, Emanuele; Vitek, Antonin; Blau, Igor Wolfgang; Niittyvuopio, Riitta; Finke, Jürgen; Cornelissen, Jan J; Passweg, Jakob; Dreger, Peter; Petersen, Eefke; Kanz, Lothar; Sanz, Jaime; Zuckerman, Tsila; Zinger, Nienke; Iacobelli, Simona; Hayden, Patrick; Czerw, Tomasz; McLornan, Donal; Yakoub-Agha, Ibrahim.

In: LEUKEMIA, Vol. 35, No. 1, 01.2021, p. 215-224.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hernández-Boluda, JC, Pereira, A, Kröger, N, Beelen, D, Robin, M, Bornhäuser, M, Angelucci, E, Vitek, A, Blau, IW, Niittyvuopio, R, Finke, J, Cornelissen, JJ, Passweg, J, Dreger, P, Petersen, E, Kanz, L, Sanz, J, Zuckerman, T, Zinger, N, Iacobelli, S, Hayden, P, Czerw, T, McLornan, D & Yakoub-Agha, I 2021, 'Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation', LEUKEMIA, vol. 35, no. 1, pp. 215-224. https://doi.org/10.1038/s41375-020-0815-z

APA

Hernández-Boluda, J. C., Pereira, A., Kröger, N., Beelen, D., Robin, M., Bornhäuser, M., Angelucci, E., Vitek, A., Blau, I. W., Niittyvuopio, R., Finke, J., Cornelissen, J. J., Passweg, J., Dreger, P., Petersen, E., Kanz, L., Sanz, J., Zuckerman, T., Zinger, N., ... Yakoub-Agha, I. (2021). Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. LEUKEMIA, 35(1), 215-224. https://doi.org/10.1038/s41375-020-0815-z

Vancouver

Hernández-Boluda JC, Pereira A, Kröger N, Beelen D, Robin M, Bornhäuser M et al. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. LEUKEMIA. 2021 Jan;35(1):215-224. https://doi.org/10.1038/s41375-020-0815-z

Bibtex

@article{60734510a2654b8787e44ffe440df9c9,
title = "Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation",
abstract = "We aimed to evaluate the determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) and to describe factors predicting the main post-HCT complications. This retrospective study by the European Society for Blood and Marrow Transplantation included 2916 myelofibrosis patients who underwent first allo-HCT from an HLA-identical sibling or unrelated donor between 2000 and 2016. After a median follow-up of 4.7 years from transplant, projected median survival of the series was 5.3 years. Factors independently associated with increased mortality were age ≥ 60 years and Karnofsky Performance Status <90% at transplant, and occurrence of graft failure, grades III-IV acute graft-vs.-host disease (aGVHD), and disease progression/relapse during follow-up. The opposing effects of chronic graft-vs.-host disease (GVHD) on non-relapse mortality and relapse incidence resulted in a neutral influence on survival. Graft failure increased in unrelated donor recipients and decreased with myeloablative conditioning (MAC) and negative donor/recipient cytomegalovirus serostatus. Risk of grades III-IV aGVHD was higher with unrelated donors and decreased with MAC. Relapse incidence tended to be higher in patients with intermediate-2/high-risk DIPSS categories and to decrease in CALR-mutated patients. Acute and chronic GVHD reduced the subsequent risk of relapse. This information has potential implications for patient counseling and clinical decision-making.",
keywords = "Europe, Female, Graft vs Host Disease/etiology, Hematopoietic Stem Cell Transplantation/adverse effects, Humans, Kaplan-Meier Estimate, Male, Primary Myelofibrosis/diagnosis, Prognosis, Proportional Hazards Models, Recurrence, Registries, Retrospective Studies, Transplantation, Homologous, Treatment Outcome",
author = "Hern{\'a}ndez-Boluda, {Juan Carlos} and Arturo Pereira and Nicolaus Kr{\"o}ger and Dietrich Beelen and Marie Robin and Martin Bornh{\"a}user and Emanuele Angelucci and Antonin Vitek and Blau, {Igor Wolfgang} and Riitta Niittyvuopio and J{\"u}rgen Finke and Cornelissen, {Jan J} and Jakob Passweg and Peter Dreger and Eefke Petersen and Lothar Kanz and Jaime Sanz and Tsila Zuckerman and Nienke Zinger and Simona Iacobelli and Patrick Hayden and Tomasz Czerw and Donal McLornan and Ibrahim Yakoub-Agha",
year = "2021",
month = jan,
doi = "10.1038/s41375-020-0815-z",
language = "English",
volume = "35",
pages = "215--224",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

AU - Hernández-Boluda, Juan Carlos

AU - Pereira, Arturo

AU - Kröger, Nicolaus

AU - Beelen, Dietrich

AU - Robin, Marie

AU - Bornhäuser, Martin

AU - Angelucci, Emanuele

AU - Vitek, Antonin

AU - Blau, Igor Wolfgang

AU - Niittyvuopio, Riitta

AU - Finke, Jürgen

AU - Cornelissen, Jan J

AU - Passweg, Jakob

AU - Dreger, Peter

AU - Petersen, Eefke

AU - Kanz, Lothar

AU - Sanz, Jaime

AU - Zuckerman, Tsila

AU - Zinger, Nienke

AU - Iacobelli, Simona

AU - Hayden, Patrick

AU - Czerw, Tomasz

AU - McLornan, Donal

AU - Yakoub-Agha, Ibrahim

PY - 2021/1

Y1 - 2021/1

N2 - We aimed to evaluate the determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) and to describe factors predicting the main post-HCT complications. This retrospective study by the European Society for Blood and Marrow Transplantation included 2916 myelofibrosis patients who underwent first allo-HCT from an HLA-identical sibling or unrelated donor between 2000 and 2016. After a median follow-up of 4.7 years from transplant, projected median survival of the series was 5.3 years. Factors independently associated with increased mortality were age ≥ 60 years and Karnofsky Performance Status <90% at transplant, and occurrence of graft failure, grades III-IV acute graft-vs.-host disease (aGVHD), and disease progression/relapse during follow-up. The opposing effects of chronic graft-vs.-host disease (GVHD) on non-relapse mortality and relapse incidence resulted in a neutral influence on survival. Graft failure increased in unrelated donor recipients and decreased with myeloablative conditioning (MAC) and negative donor/recipient cytomegalovirus serostatus. Risk of grades III-IV aGVHD was higher with unrelated donors and decreased with MAC. Relapse incidence tended to be higher in patients with intermediate-2/high-risk DIPSS categories and to decrease in CALR-mutated patients. Acute and chronic GVHD reduced the subsequent risk of relapse. This information has potential implications for patient counseling and clinical decision-making.

AB - We aimed to evaluate the determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) and to describe factors predicting the main post-HCT complications. This retrospective study by the European Society for Blood and Marrow Transplantation included 2916 myelofibrosis patients who underwent first allo-HCT from an HLA-identical sibling or unrelated donor between 2000 and 2016. After a median follow-up of 4.7 years from transplant, projected median survival of the series was 5.3 years. Factors independently associated with increased mortality were age ≥ 60 years and Karnofsky Performance Status <90% at transplant, and occurrence of graft failure, grades III-IV acute graft-vs.-host disease (aGVHD), and disease progression/relapse during follow-up. The opposing effects of chronic graft-vs.-host disease (GVHD) on non-relapse mortality and relapse incidence resulted in a neutral influence on survival. Graft failure increased in unrelated donor recipients and decreased with myeloablative conditioning (MAC) and negative donor/recipient cytomegalovirus serostatus. Risk of grades III-IV aGVHD was higher with unrelated donors and decreased with MAC. Relapse incidence tended to be higher in patients with intermediate-2/high-risk DIPSS categories and to decrease in CALR-mutated patients. Acute and chronic GVHD reduced the subsequent risk of relapse. This information has potential implications for patient counseling and clinical decision-making.

KW - Europe

KW - Female

KW - Graft vs Host Disease/etiology

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Primary Myelofibrosis/diagnosis

KW - Prognosis

KW - Proportional Hazards Models

KW - Recurrence

KW - Registries

KW - Retrospective Studies

KW - Transplantation, Homologous

KW - Treatment Outcome

U2 - 10.1038/s41375-020-0815-z

DO - 10.1038/s41375-020-0815-z

M3 - SCORING: Journal article

C2 - 32286544

VL - 35

SP - 215

EP - 224

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 1

ER -